Navigation Links
Human Trial Results Show Plant Extract Tops Drug at Regulating Blood Sugar Levels; Huge Market Seen for Newly Developed Food Additive Emulin™
Date:9/16/2008

Human trials show that Emulin(TM), a plant-based extract, is better than metformin, the leading Type 2 diabetes medication, at controlling blood sugar levels in human beings.

Winter Haven, FL (PRWEB) September 16, 2008 -- A newly developed plant extract can regulate blood sugar levels in Type 2 diabetics better than a leading prescription drug, according to the results of human trials released today.

The trial results involving Emulin™, an all-natural compound derived from tropical fruits, are even more significant now that major research shows just how critical it is for diabetics to control long-term blood sugar levels to stave off heart attacks and other complications of this disease.

"The results show that Emulin™ alone is better than the leading prescription drug at reducing blood glucose levels in Type 2 diabetics," said Daryl Thompson, a scientific director at www.atmmetabolics.com [ATM Metabolics]], the Winter Haven Fla.-based firm that developed the food additive. "With the numbers of diabetics worldwide expected to grow from an estimated 150 million now to 300 million by 2025, the market for Emulin™ is staggering."

According to Thompson, the plant-derived compound acts like insulin when ingested. "We designed Emulin™ to lessen the glycemic impact of high-sugar foods like colas and candies or high-carbohydrate refined breads," Thompson said.

In a double-blind, placebo-controlled, FDA-approved human trial, 40 Type 2 diabetics consumed three time a day (before each meal) a capsule containing either 250 mg of Emulin™ or a placebo. Participants were divided into four sub-groups: placebo only; placebo and metformin, a leading prescription medication to control glucose absorption in Type 2 diabetics; Emulin™ only; and Emulin™ with metformin.

The study was discontinued after one week for the two groups taking metformin, and after two weeks for the other groups.

At the end of one week, fasting blood glucose levels remained the same or increased slightly for the placebo control group and decreased 2 percent in the metformin only group. Fasting blood glucose levels decreased 11 percent and 28 percent respectively, however, for the Emulin™ only group and the Emulin™ plus metformin group.

After one week, peak blood sugar level, meaning the level two hours after a glucose tolerance test, increased 4 percent in the placebo only group, was unchanged in the Emulin™ only group; and decreased 10 percent in the metformin only group and 12 percent in the metformin plus Emulin™ group.

At the end of two weeks, both fasting blood glucose and peak blood glucose had increased 1 percent in the placebo only group yet declined 20 percent in the Emulin™ only group.

The study results will be presented formally during the UCLA Symposium on Metabolic Diseases in January 2009. The independent company that conducted the human trial is dgd Research, Inc., of San Antonio, Texas.

About ATM Metabolics
ATM Metabolics is an early stage technology development and commercialization company focused on technologies for diabetic, nutrition, and diet products. The firm constantly researches and develops novel therapeutics for conditions that include Types 1 and 2 diabetes and other chronic or debilitating conditions. More information: http://www.atmmetabolics.com.

# # #

Read the full story at http://www.prweb.com/releases/2008/09/prweb1335264.htm


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved

Related biology technology :

1. Expiry of Hart-Scott-Rodino Waiting Period for JUVISTA(R) (Human TGF BETA 3)
2. New Initiative Has Shocking Effect: Thousands of Missourians with Abnormal Chromosome Structures Are Not Human
3. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
4. Human Genome Sciences Announces $40 Million Milestone Payment Related to Albuferon(R) Development
5. Novocell Announces Discovery Linking Key Cancer Cell Signaling Pathways With Proliferation and Self-Renewal of Human Embryonic Stem Cells
6. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Thomas Weisel Partners Conference
7. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at BioCentury-Thomson Financial Investment Conference
8. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Bear Stearns Conference
9. Human Pheromone Sciences Enters Into Agreement to Reposition and Promote its Natural Attraction(R) Brand
10. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Merrill Lynch Conference
11. Premier Research Appoints Global Head of Human Resources
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)...  Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing ... that Linda Marbán, Ph.D, president and chief executive officer, is ... Cowen and Company 37th Annual Health Care Conference ... Boston, MA 29th Annual ROTH ... pm ET) Dana Point, CA ...
(Date:2/23/2017)... CARDIFF, UK (PRWEB) , ... February 22, 2017 ... ... for optics and photonics , have been named Fellows of the Society this ... and technical contributions in the multidisciplinary fields of optics, photonics, and imaging as ...
(Date:2/22/2017)... ... February 22, 2017 , ... Park Systems , ... AFM Luncheon for all SPIE attendees and Park customers on Feb. ... block from the San Jose Convention Center. The luncheon will feature a talk ...
(Date:2/22/2017)... Washington, PA (PRWEB) , ... ... ... Omnia-Prova Education Collaborative (TOPEC), the leading medical education provider of women’s ... with Commendation by the Accreditation Council for Continuing Medical Education (ACCME). ACCME’s ...
Breaking Biology Technology:
(Date:2/13/2017)... 2017 Former 9/11 Commission border counsel and ... Janice Kephart of Identity Strategy Partners, LLP, today ... "Executive Order: Protecting the Nation From Foreign Terrorist ... "As President Trump,s ,Travel Ban, Executive Order gains ... banned the travel ban, it is important that our ...
(Date:2/8/2017)... 7, 2017  Aware, Inc. (NASDAQ: AWRE ), ... financial results for its quarter and year ended December 31, ... 2016 was $3.9 million compared to $6.9 million in the ... of 2016 was $0.6 million compared to $2.6 million in ... quarter of 2016 was $0.5 million, or $0.02 per diluted ...
(Date:2/7/2017)... , Feb. 7, 2017   MedNet Solutions , ... entire spectrum of clinical research, is pleased to announce ... , its innovative, highly flexible and award winning eClinical ... customers. iMedNet is a proven Software-as-a-Service (SaaS) ... Data Capture (EDC), but also delivers an entire suite ...
Breaking Biology News(10 mins):